Brand vs. Compounded GLP-1 Pricing

Why RightFit separates brand and compounded GLP-1 pricing

FDA-approved branded GLP-1 drugs and compounded GLP-1 preparations are different product and regulatory categories. Their telehealth prices can be compared as separate market observations, but they should not be averaged together without clearly labeling what is being combined.

Compounded semaglutide

Manufactured semaglutide products

Compounded tirzepatide

Manufactured tirzepatide products

What “brand” means in this report

RightFit uses branded or manufactured product records when the provider is offering a named FDA-approved product such as Wegovy or Zepbound. The brand identity is tied to the specific product and its approved prescribing information, not merely to the ingredient name.

A provider advertising semaglutide is not automatically offering Wegovy, and a provider advertising tirzepatide is not automatically offering Zepbound. The exact product must be established from the source.

What “compounded” means in this report

A compounded medication is prepared under a compounding framework rather than approved by FDA through a new or abbreviated drug application. FDA states that compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.

RightFit therefore stores compounded semaglutide and compounded tirzepatide as separate formulation records rather than treating them as lower-priced versions of FDA-approved brands.

Why the public price gap can be large

Brand-name and compounded telehealth offers can use very different supply chains, pharmacy arrangements, manufacturer pricing, clinical-service models, and discount structures. A branded product may be purchased through a retail or manufacturer-supported cash-pay pathway while the telehealth company charges separately for care. A compounded program may bundle medication, provider review, supplies, and shipping into one recurring amount.

Those structural differences can create large headline price gaps even before promotions or memberships are considered. The gap should be documented, but the comparison should not erase the product distinction.

The same provider can sell both categories

Some telehealth companies publish both compounded and FDA-approved brand options. That is useful for comparison because it shows that the provider itself may use different pricing models depending on the product. One program may be bundled and cash pay, while the brand pathway may involve insurance support or a separate medication transaction.

RightFit attaches pricing and fees to the specific provider program rather than labeling the provider as simply “brand” or “compounded.”

Membership structure can distort a headline comparison

A compounded program can have a single all-in price, while a brand-access program may require a separate membership or clinical-care fee. The reverse can also occur. A fair comparison must identify every required recurring component rather than treating the medication amount as the entire program cost.

RightFit keeps medication prices and program fees separate. That lets readers see the provider’s own pricing while still understanding the required recurring total when all components are verified.

Promotions should be compared within category

Starter discounts and prepaid monthly equivalents are common in compounded programs, while brand programs can use manufacturer savings, first-month care discounts, or other conditional offers. Those discounts answer different questions.

The research layer therefore separates normal pricing from promotional pricing before comparing product categories. A temporary compounded starter price should not be used as the permanent compounded market price, and a manufacturer savings amount should not be treated as a universal brand retail price.

The September 2026 dataset illustrates the category split

In RightFit’s September 2026 launch dataset, normal-price compounded semaglutide observations occupied a much lower public price band than the manufactured semaglutide observations. The same broad pattern appeared for tirzepatide. That difference is a feature of the observed telehealth market, but it needs to remain labeled by product category.

A single average across both categories would mainly describe how many observations came from each category rather than giving a meaningful price for a specific product.

Why manufactured observations can vary widely too

FDA-approved brand pricing is not one fixed telehealth number. Providers can publish different care fees, pharmacy pathways, self-pay arrangements, or cash prices. Manufacturer-supported programs can also have separate eligibility rules.

For that reason, manufactured-product rows still need provider, product, fee, and source context even after they are separated from compounded rows.

Why compounded observations can vary widely

Compounded programs can differ by formulation, pharmacy, supply length, route, concentration, dose-pricing policy, included care, shipping, and prepaid term. Two compounded semaglutide programs are not necessarily identical commercial offers, even though they belong in the same broad preparation category.

RightFit keeps those program attributes so a compounded-market median can be interpreted as a summary of observed offers rather than a claim that every compounded product is the same.

Regulatory category is independent from price

The regulatory distinction does not disappear when a product is inexpensive or expensive. FDA-approved products remain FDA-approved products; compounded drugs remain unapproved compounded preparations. RightFit does not infer regulatory status from price, provider reputation, pharmacy marketing, or ingredient name.

FDA has also warned telehealth companies against calling compounded drugs generic versions of approved drugs, describing them as the same as FDA-approved drugs, or implying that the compounded product has been reviewed or approved by FDA.

State availability can differ between categories

A provider may offer a compounded program in one state while a brand-access pathway has different availability, or vice versa. Pharmacy networks and product-specific rules can differ. RightFit therefore stores state coverage at the provider-program level rather than assigning one blanket state list to the provider.

How to compare brand and compounded prices responsibly

• Identify the exact product or formulation before comparing the price.
• Separate FDA-approved brands from compounded preparations.
• Compare normal recurring prices before promotional prices.
• Add verified required program or membership fees.
• Keep prepaid monthly equivalents attached to their commitment.
• Check what clinical services and shipping are included.
• Preserve dose, quantity, and formulation conditions.
• Confirm product-level state availability.
• Use current provider-primary sources for commercial facts.
• Do not turn the lowest price into a clinical recommendation.

What this research can tell you

The brand-versus-compounded analysis can show how public telehealth pricing differs by product category, how much of the visible market is promotional, and how provider business models affect the headline price. It can also show which providers offer both categories and how their fee structures differ.

What this research cannot tell you

The analysis cannot determine which product is appropriate for an individual, whether a specific compounded preparation is equivalent to an approved drug, or what an individual will pay after insurance, manufacturer programs, clinical eligibility, and final checkout.

Those limits are important because price is only one dimension. RightFit’s role is to describe the public commercial market accurately while leaving treatment decisions to licensed healthcare professionals.

Why the dataset should remain segmented over time

As new products and formulations enter the telehealth market, a longitudinal price tracker can become misleading if it silently changes what is inside the average. RightFit preserves product and preparation categories so future month-to-month comparisons can distinguish actual price movement from changes in the mix of observations.

That makes the September 2026 baseline more useful: future reports can compare compounded with compounded and manufactured with manufactured rather than flattening unlike markets together.

Bottom line

The public telehealth market shows a meaningful price difference between many compounded GLP-1 programs and FDA-approved branded products. The correct interpretation is that they are different product categories with different commercial structures, not that one is a generic or interchangeable substitute for the other.

RightFit keeps the categories separate so price comparisons remain transparent about what is actually being offered.

Why “generic” language would distort the price analysis

If a compounded GLP-1 were labeled as a generic version of an approved brand, a reader could reasonably interpret the price gap as a simple brand-versus-generic discount. FDA specifically warns against that framing for compounded drugs. RightFit therefore treats the price comparison as a comparison between different product categories, not a generic-substitution analysis.

That distinction also affects how the data should be summarized. A report can say that verified compounded observations occupy a lower public price band than verified manufactured-brand observations in the dataset. It should not say that the same approved drug is available at the compounded price.

Cash-pay eligibility can also create apparent price gaps

Brand-name pricing can depend on manufacturer programs, pharmacy channels, insurance status, or other eligibility rules, while many compounded programs publish direct cash-pay rates. Those different access pathways can widen or narrow the visible price gap without changing the underlying regulatory distinction. RightFit keeps eligibility language with the observation so a conditional brand price is not treated as universally available.

A lower compounded-program price and a higher branded cash price are not evidence that the products are interchangeable. The comparison is commercial: what each verified program costs under its published terms. Regulatory status, formulation, approved labeling, pharmacy pathway, and clinical appropriateness remain separate questions.

Comparison rule for future reports

Future brand-versus-compounded reports should preserve the same segmentation even if the provider set changes. That allows a change in price to be distinguished from a change in which product categories happened to be included in the sample.